Sandbox Reserved 431
From Proteopedia
(→Introduction) |
|||
| Line 8: | Line 8: | ||
===Introduction=== | ===Introduction=== | ||
<scene name='Sandbox_Reserved_431/Monomer/1'>Monomer</scene> | <scene name='Sandbox_Reserved_431/Monomer/1'>Monomer</scene> | ||
| + | |||
| + | → Function: enzyme that decreases the amount of insulin receptor in the cell, which increases the effectiveness of the insulin produced in the body | ||
| + | |||
| + | → Why important to diabetes: type 2 diabetes is caused by the inability to use insulin effectively. Since phosphatase inhibitors increase the effectiveness of insulin in the cell, it has proved effective in treating type 2 diabetes | ||
| + | |||
| + | → Nonselective competitive inhibitor | ||
| + | |||
| + | → Multiple ligand binding sites – inhibitor binds with catalytic site in “open” position. Proves competitive inhibition | ||
| + | |||
| + | → Formed by being genetically manipulated | ||
===Overall Structure=== | ===Overall Structure=== | ||
Revision as of 04:01, 5 March 2012
| This Sandbox is Reserved from January 19, 2016, through August 31, 2016 for use for Proteopedia Team Projects by the class Chemistry 423 Biochemistry for Chemists taught by Lynmarie K Thompson at University of Massachusetts Amherst, USA. This reservation includes Sandbox Reserved 425 through Sandbox Reserved 439. |
Contents |
Phosphatase Inhibitor complexes: pdb 1nny
|
Introduction
→ Function: enzyme that decreases the amount of insulin receptor in the cell, which increases the effectiveness of the insulin produced in the body
→ Why important to diabetes: type 2 diabetes is caused by the inability to use insulin effectively. Since phosphatase inhibitors increase the effectiveness of insulin in the cell, it has proved effective in treating type 2 diabetes
→ Nonselective competitive inhibitor
→ Multiple ligand binding sites – inhibitor binds with catalytic site in “open” position. Proves competitive inhibition
→ Formed by being genetically manipulated
Overall Structure
Binding Interactions
-This is a competitive inhibitor
-It has good selectivity over other phosphatases
-Ligand binds via 2 binding sites
-Binding is reversible
<
Additional Features
Credits
Introduction - Jill Carlson
Overall Structure - Polina Berdnikova
Drug Binding Site - Brett Clinton
Additional Features - James Hamblin
